Protocols
34 protocol(s) meet the specified criteria
Disease Site: Lymphoid Leukemia
Protocol No.TitleStatus
10-CBAA multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) for transplantation in pediatric and adult patients with hematologic malignancies and other indicationsOpen
14-1999Biomarker-Based Radiation Dosimetry ProjectOpen
A-TREATAmerican Trial Using Tranexamic Acid in Thrombocytopenia (A-TREAT) Open
ACCL1333A Phase III Randomized, Open Label, Multi-center Study on the Safety and Efficacy of Apixaban for Thromboembolism Prevention versus No Systemic Anticoagulant Prophylaxis during Induction Chemotherapy in Children with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) or Lymphoma (T or B cell) Treated with Pegylated (PEG) L-AsparaginaseOpen
BMA117159A Phase I Open-Label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Clinical Activity of the Antibody Drug Conjugate GSK2857916 in Subjects with Relapsed/Refractory Multiple Myeloma and Other Advanced Hematologic malignancies Expressing BCMAOpen
BMT-CTN-1101BMT CTN 1101: A Multi-Center, Phase III, Randomized Trial of Reduced Intensity (RIC) Conditioning and Transplantation of Double Unrelated Umbilical Cord Blood (dUCB) versus HLA-Haploidentical Related Bone Marrow (haplo-BM) for Patients with Hematologic MalignanciesOpen
BMT-CTN-1202Prospective Multi-Center Cohort for the Evaluation of Biomarkers Predicting Risk of Complications and Mortality Following Allogeneic HCTOpen
BMT-CTN-1205BMTCTN 1205: Easy-to-Read Informed Consent (ETRIC) for Hematopoietic Cell Transplantation Clinical TrialsOpen
CALGB10403An Intergroup Phase II Clinical Trial for Adolescents and Young Adults with Untreated Acute Lymphoblastic Leukemia (ALL)Open (affiliates only)
CALGB10404A Genetic, Risk-Stratified Randomized Phase II Study of Four Fludarabine/Antibody Combinations for Patients with Symptomatic, Previously Untreated Chronic Lymphocytic Leukemia Open (affiliates only)
CLFG316X2202A randomized, open label, controlled, multiple dose study to evaluate the clinical efficacy, safety, tolerability, pharmacokinetics and pharmacodynamics of LFG316 in patients with transplant associated microangiopathy after hematopoietic precursor cell transplantationOpen
COG-AALL05B1A Children's Oncology Group Protocol for Collecting and Banking Relapsed Acute Lymphoblastic Leukemia Research SpecimensOpen
COG-AALL08B1Classification of Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)Open
COG-AALL0932Treatment of Patients with Newly Diagnosed Standard Risk B-Precursor Acute Lymphoblastic Leukemia (ALL)Open
COG-AALL1231A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239; IND# 58443) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T- Lymphoblastic Leukemia (T-ALL)and T- Lymphoblastic Lymphoma (T-LLy)Open
COG-AALL1331Risk-Stratified Randomized Phase III Testing of Blinatumomab (IND# 117467, NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)Open
COG-ACCL1131A Phase III Open-Label Trial of Caspofungin vs. Azole Prophylaxis for Patients at High-Risk for Invasive Fungal Infections (IFI) Following Allogeneic Hematopoietic Cell Transplantation (HCT)Open
COGAALL1131A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (IND#73789, NSC#732517) in Patients with Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive MutationsOpen
E1910A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-negative B lineage Acute Lymphoblastic Leukemia in Adults.Open
EBV-CTL-201Multicenter Expanded Access Protocol of Allogeneic Epstein-Barr Virus Cytotoxic T Lymphocytes (EBV-CTLs) for Patients with EBV-Associated Lymphomas and Lymphoproliferative Disorders in Immunocompromised Patients for Whom There are No Other Comparable OptionsOpen
GS-US-339-0102A Phase 2, Open-Label Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacodynamics of GS-9973 in Subjects with Relapsed or Refractory Hematologic MalignanciesOpen
INCB-8424-269A Phase 2 Study of the JAK1/JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High-Risk CRLF2-Rearranged and/or JAK Pathway–Mutant Acute Lymphoblastic LeukemiaOpen
LCCC0905Graft-Versus-Host Disease Solid Tissue ProcurementOpen
LCCC1241Complementary and Alternative medicine use at UNC clinicsOpen
LCCC1314A phase II, placebo-controlled, double-blind, randomized trial of pregabalin for the prophylaxis of granulocyte colony stimulating factor (GCSF)-induced bone painOpen
LCCC1404Evaluating the ability of electronic patient symptom reporting to reduce symptom burden during hospitalization for intensive chemotherapyOpen
LCCC1535Understanding Treatment Decision-making and Psychological Distress in Patients with Advanced CancerOpen
LCCC1538Geriatric Assessment Reporting in Real Time (GARRT) in non-electively hospitalized older cancer patients: feasibility, impact, and clinician acceptance.Open
LCCC1542Leukemia Specific Splice Isoforms as Neo-Antigens for T-cell Immunotherapy Open
LCCC1602Health services use and social outcomes of adult survivors of childhood cancerOpen
LTE1401Natural History and Biology of Long-Term Late Effects Following Hematopoietic Cell Transplant for Childhood Hematologic MalignanciesOpen
TGTX-LAB-001Screening Protocol to Determine High-risk Cytogenetic Features in Patients With Previously-treated CLL That May be Eligible for TG Therapeutics Trial UTX-IB-301Open (affiliates only)
UTX-IB-301A Phase 3, Randomized, Study to Assess the Efficacy and Safety of Ublituximab in Combination with Ibrutinib Compared to Ibrutinib Alone, in Patients with Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL).Open (affiliates only)
UTX-TGR-304A Phase 3, Randomized Study to Assess the Efficacy and Safety of Ublituximab in Combination with TGR-1202 Compared to Obinutuzumab in Combination with Chlorambucil in Patients with Chronic Lymphocytic Leukemia (CLL)Open (affiliates only)